Here’s a preview of the featured content to watch for this week on Drug Topics®.
Coronavirus Research News
With an estimated 165 million COVID-19 vaccine doses administered and 553,000 deaths in the US as of this article’s press time, keeping up with pandemic news is more important than ever. Check back to Drug Topics®to stay informed on the latest coronavirus-related news and research.
Read more coronavirus-related news.
The Latest from Total Pharmacy®: Pharmacogenomic Testing for Mental Health Care in Community Pharmacy
A recent Community Pharmacy Foundation project delved into the fascinating world of pharmacogenomics. Stephanie Davis, PharmD, BCACP, part-owner of Goodrich Pharmacy in Anoka, Minnesota, worked on the project with Elise Durgin, PharmD, BCPS, and Emily Hulke, PharmD. They explained to patients that pharmacogenomic testing could provide a piece to the puzzle in helping to identify the most appropriate medication.
Return Solutions eBook Now Available
Reclaim time spent tracking expired product return credits so you can focus on what matters most: your customers and your business. Learn how to by downloading the eBook, Optimize Medication Returns in the Pharmacy with Return Solutions.
Drug Topics® Journal, April 2021 Digital Edition
The April 2021 digital edition of Drug Topics Journal is now available on DrugTopics.com. In this issue, Drug Topics® covers the American Pharmacists Association 2021 Annual Meeting, and our cover story considers the importance of scaling up telepharmacy for the future.
Medical World News Updates
In an interview with Drug Topics®, Scott Caravello of Galva Pharmacy and Cameron Deemer of DrFirst will discuss the latest in artificial intelligence (AI) and how Galva Pharmacy became the first pharmacy in the country to integrate an in-workflow, AI solution that accurately structures, codifies, and backfills information gaps in electronic prescriptions.
This Week on Total Pharmacy®
A.J. Barbarito, Esq; Steven Bennet, Esq; and Jesse C. Dresser, Esq, from Frier Levitt discuss different aspects of drug reimbursement laws at federal and state levels.
Stay tuned to read the article at totalpharmacy.com.
In Case You Missed It: Study Reports No Evidence of Liver Toxicity from Use of Hemp-Derived CBD Products
Results of a recent study from Validcare investigating the safety of hemp-derived cannabidiol (CBD) products reported no evidence of liver disease and no increase in the prevalence of elevated liver function tests when compared with a population with analogous rates of medical conditions, according to a news release.